Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results

doi:10.5501/wjv.v6.i4.59

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12581)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-8) series.

Item

Count

PDF

680

WORD

398

HTML

4730

Figures (1-2)

264

Tables (1-8)

425

Sum=6497

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

1237

Download

1567

Sum=2804

Publishing Process of This Article

Item

Count

Browse

1232

Download

2048

Sum=3280

Nov 12, 2017 (publication date) through Nov 7, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Virol. Nov 12, 2017; 6(4): 59-72
Published online Nov 12, 2017. doi: 10.5501/wjv.v6.i4.59

Table 3 SVR12 rates for 508 patients who initiated therapy with simeprevir- and/or sofosbuvir-based treatment regimens, calculated on an intention-to-treat basis, with imputed data on 14 patients

	SVR12 rates
	SVR/total (%)	95%CI, %
All treatments	372/508 (73)	69-77
SMV/SOF ± RBV	153/178 (86)	80-91
“COSMOS-like" cohort	117/130 (90)	83-94
SOF/RBV	144/234 (62)	55-68
Genotype
1	45/102 (44)	34-54
2	57/69 (83)	71-90
3	35/52 (67)	53-79
4	7/11 (64)	32-88
SOF/PEG/RBV	75/96 (78)	68-86

SVR: Sustained virological response; SMV: Simeprevir; SOF: Sofosbuvir; RBV: Ribavirin; PEG: Pegylated interferon.

Citation: Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol 2017; 6(4): 59-72
URL: https://www.wjgnet.com/2220-3249/full/v6/i4/59.htm
DOI: https://dx.doi.org/10.5501/wjv.v6.i4.59